Insider · CIK 0001223348
Charles F Wagner Jr
Files at TJX (TJX COMPANIES INC /DE/), VRTX (VERTEX PHARMACEUTICALS INC / MA). First filing Nov 21, 2023, latest Jan 8, 2026.
In brief
Charles F Wagner Jr files SEC Form 4 as CFO and director at VRTX (VERTEX PHARMACEUTICALS INC / MA), and also at TJX (TJX COMPANIES INC /DE/). Since Nov 21, 2023, Charles F Wagner Jr has reported 0 open-market buys worth $0 and 4 open-market sells worth $13M, the latest filed on Jan 8, 2026.
A track record needs three past buys with six months of prices behind them; Charles F Wagner Jr has 0, so none is measured yet.
The newest scored trade: sold $4.4M of VRTX on Jan 6, 2026, filed Jan 8, 2026, scored 18 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $11M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
VRTX: VERTEX PHARMACEUTICALS INC / MA
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 18Weak | VERTEX PHARMACEUTICALS INC / MA | $4.4M 9,532 shares | -20% | +28% from low-9% from high | |
| 45Moderate | VERTEX PHARMACEUTICALS INC / MA | $6.4M 14,000 shares | -27% | +26% from low-10% from high | |
| 42Moderate | VERTEX PHARMACEUTICALS INC / MA | $1.6M 3,000 shares | -6% | +12% from low-3% from high | |
| 42Moderate | VERTEX PHARMACEUTICALS INC / MA | $1.0M 3,000 shares | -6% | +26% from low-8% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 6, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | 9,532 0.00% of outstanding | $4.4M | Jan 6, 2026 | $6.4M |
| Dec 3, 2025 | VRTX VERTEX PHARMACEUTICALS INC / MA | 7,000 0.00% of outstanding | $3.2M | Dec 3, 2025 | none |
| Dec 3, 2025 | VRTX VERTEX PHARMACEUTICALS INC / MA | 7,000 0.00% of outstanding | $3.2M | Dec 3, 2025 | none |
| Mar 10, 2025 | VRTX VERTEX PHARMACEUTICALS INC / MA | 3,298 0.00% of outstanding | $1.6M | Mar 10, 2025 | none |
| Nov 12, 2024 | VRTX VERTEX PHARMACEUTICALS INC / MA | 3,000 0.00% of outstanding | $1.6M | Nov 11, 2024 | none |
| Nov 20, 2023 | VRTX VERTEX PHARMACEUTICALS INC / MA | 3,000 0.00% of outstanding | $1.0M | Nov 20, 2023 | none |
Transactions
Every row this insider has filed, 22 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | TJX TJX COMPANIES INC /DE/ | AGrant or award Deferred Stock Unitsderivative | +637 | $0.00 | $0 | 3,126 | Jun 11, 2026 |
| Jun 9, 2026 | TJX TJX COMPANIES INC /DE/ | AGrant or award Deferred Stock Unitsderivative | +27 | $0.00 | $0 | 3,153 | Jun 11, 2026 |
| Jun 9, 2026 | TJX TJX COMPANIES INC /DE/ | AGrant or award Deferred Stock Unitsderivative | +637 | $0.00 | $0 | 3,126 | Jun 11, 2026 |
| Jun 9, 2026 | TJX TJX COMPANIES INC /DE/ | AGrant or award Deferred Stock Unitsderivative | +27 | $0.00 | $0 | 3,153 | Jun 11, 2026 |
| Feb 24, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | FTax withholding Common Stock | -1,744 | $485.11 | $846k | 47,042 | Feb 26, 2026 |
| Feb 17, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | AGrant or award Common Stock | +7,365 | $0.00 | $0 | 51,080 | Feb 19, 2026 |
| Feb 17, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | FTax withholding Common Stock | -2,294 | $483.75 | $1.1M | 48,786 | Feb 19, 2026 |
| Feb 13, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | FTax withholding Common Stock | -4,565 | $487.76 | $2.2M | 43,715 | Feb 18, 2026 |
| Feb 10, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | FTax withholding Common Stock | -3,045 | $468.41 | $1.4M | 48,280 | Feb 12, 2026 |
| Jan 22, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | AGrant or award Common Stock | +9,440 | $0.00 | $0 | 47,165 | Jan 26, 2026 |
| Jan 22, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | AGrant or award Common Stock | +4,160 | $0.00 | $0 | 51,325 | Jan 26, 2026 |
| Jan 6, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | MOption exercise Common Stock10b5-1 | +9,532 | $189.38 | $1.8M | 47,257 | Jan 8, 2026 |
| Jan 6, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | SOpen-market sale Common Stock10b5-1 | -9,532 | $461.00 | $4.4M | 37,725 | Jan 8, 2026 |
| Jan 6, 2026 | VRTX VERTEX PHARMACEUTICALS INC / MA | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,532 | $0.00 | $0 | 0 | Jan 8, 2026 |
| Dec 3, 2025 | VRTX VERTEX PHARMACEUTICALS INC / MA | SOpen-market sale Common Stock10b5-1 | -7,000 | $451.00 | $3.2M | 44,725 | Dec 5, 2025 |
| Dec 3, 2025 | VRTX VERTEX PHARMACEUTICALS INC / MA | SOpen-market sale Common Stock10b5-1 | -7,000 | $461.00 | $3.2M | 37,725 | Dec 5, 2025 |
| Jun 10, 2025 | TJX TJX COMPANIES INC /DE/ | AGrant or award Deferred Stock Unitsderivative | +793 | $0.00 | $0 | 2,469 | Jun 12, 2025 |
| Jun 10, 2025 | TJX TJX COMPANIES INC /DE/ | AGrant or award Deferred Stock Unitsderivative | +21 | $0.00 | $0 | 2,489 | Jun 12, 2025 |
| Jun 10, 2025 | TJX TJX COMPANIES INC /DE/ | AGrant or award Deferred Stock Unitsderivative | +793 | $0.00 | $0 | 2,469 | Jun 12, 2025 |
| Jun 10, 2025 | TJX TJX COMPANIES INC /DE/ | AGrant or award Deferred Stock Unitsderivative | +21 | $0.00 | $0 | 2,489 | Jun 12, 2025 |
| Nov 11, 2024 | VRTX VERTEX PHARMACEUTICALS INC / MA | SOpen-market sale Common Stock10b5-1 | -3,000 | $518.27 | $1.6M | 44,137 | Nov 13, 2024 |
| Nov 20, 2023 | VRTX VERTEX PHARMACEUTICALS INC / MA | SOpen-market sale Common Stock10b5-1 | -3,000 | $349.88 | $1.0M | 46,693 | Nov 21, 2023 |
Questions about Charles F Wagner Jr
Answered from the filings on this page, as of the latest one.
Is Charles F Wagner Jr buying or selling?
In the last 12 months Charles F Wagner Jr reported 0 open-market buys worth $0 and 2 open-market sells worth $11M on SEC Form 4; the latest was sold $4.4M of VRTX on Jan 6, 2026. Grants, option exercises and tax withholding are not counted.
How did Charles F Wagner Jr's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Charles F Wagner Jr has 0.
Where does Charles F Wagner Jr file Form 4?
Charles F Wagner Jr has filed Form 4 at VRTX (VERTEX PHARMACEUTICALS INC / MA) as EVP & Chief Financial Officer; TJX (TJX COMPANIES INC /DE/). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.